Live Breaking News & Updates on Sufentanil Sublingual Tablet

Stay updated with breaking news from Sufentanil sublingual tablet. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update

Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA. ....

United States , Andrea Angelini , Jeffrey Deweese , Ashley Sikand , Vince Angotti , University Of Padova , Osmotica Pharmaceuticals , European Medicines Agency , Office Rhinology Procedures , Avion Pharmaceuticals , Acelrx Pharmaceuticals Inc , Department Of Defense , Sovereign Pharmaceuticals , Prnewswire Acelrx Pharmaceuticals Inc , Alora Pharmaceuticals , Uniformed Services University Of The Health Sciences , Exchange Commission , Acella Pharmaceuticals , Drug Administration , Niyad Emergency Use Authorization , New Drug Application , Chief Executive Officer , Emergency Use Authorization , Recent Corporate , European Launch , Otolaryngology Case ,

AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures

/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of. ....

United States , Ashley Sikand , Pamela Palmer , Las Vegas , Office Rhinology Procedures , Acelrx Pharmaceuticals Inc , European Medicines Agency , American Society Of Anesthesiologists , Prnewswire Acelrx Pharmaceuticals Inc , Otolaryngology Case , Sufentanil Sublingual Tablet , Perioperative Pain Management , In Office Rhinology Procedures , Throat Consultants , American Society , Physical Status , Chief Medical Officer , Acelrx Pharmaceuticals ,

AcelRx Pharma (ACRX) Announces Peer-Reviewed Publication On the Use of DSUVIA

AcelRx Pharma (ACRX) Announces Peer-Reviewed Publication On the Use of DSUVIA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Ashley Sikand , Pamela Palmer , Las Vegas , Office Rhinology Procedures , Acelrx Pharmaceuticals Inc , American Society Of Anesthesiologists , Otolaryngology Case , Sufentanil Sublingual Tablet , Perioperative Pain Management , In Office Rhinology Procedures , Throat Consultants , American Society , Physical Status , Chief Medical Officer ,

AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures

/PRNewswire/ AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative. ....

United States , Hisham Seify , Pamela Palmer , Acelrx Pharmaceuticals Inc , Surgery Journal Open Forum , European Commission , Prnewswire Acelrx Pharmaceuticals Inc , Plastic Surgery Procedures , Sufentanil Sublingual Tablet , Improve Patient , Newport Plastic Surgery , Newport Beach , Aesthetic Surgery Journal Open Forum , Acelrx Chief Medical Officer , Acelrx Pharmaceuticals ,

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Full year 2020 revenues of $5.4 million compared to $2.3 million in 2019
News provided by
Share this article
Share this article
REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full year 2020 financial results.
Last year we achieved many important milestones and objectives that set the foundation for the growth of DSUVIA® in 2021 and beyond, despite the global pandemic, said Vince Angotti, Chief Executive Officer of AcelRx. Like many other companies in our space, COVID has had an impact on the pace of approvals and adoption of DSUVIA as formulary review meetings and elective surgeries have been postponed. However, with vaccine ....

United States , Michael Wolff , Christian Tvetenstrand , Zimmer Biomet , Vince Angotti , Richardd Urman , Koth Cassavaugh , Department Of Defense Do , Harvard Medical School , University Hospitals Cleveland Medical Center , Perioperative Research At Brigham , Acelrx Pharmaceuticals Inc , Us Army , Reconstructive Surgery Center , Us Army Skos , Acelrx Pharmaceuticals , Chief Executive Officer , Recent Highlights , Associate Professor , Perioperative Research , Harvard Medical , Opioid Use , Reduced Time , Sublingual Sufentanil , Ambulatory Surgery Setting , Clinical Anesthesia ,